NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free ADVM Stock Alerts $1.77 +0.07 (+4.12%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.65▼$1.7950-Day Range$0.80▼$2.8152-Week Range$0.68▼$2.97Volume1.44 million shsAverage Volume2.38 million shsMarket Capitalization$366.67 millionP/E RatioN/ADividend YieldN/APrice Target$4.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Adverum Biotechnologies alerts: Email Address Adverum Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside163.7% Upside$4.67 Price TargetShort InterestHealthy2.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.47Based on 6 Articles This WeekInsider TradingAcquiring Shares$135,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.24) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.68 out of 5 starsMedical Sector104th out of 947 stocksBiological Products, Except Diagnostic Industry12th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingAdverum Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.67, Adverum Biotechnologies has a forecasted upside of 163.7% from its current price of $1.77.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.62% of the outstanding shares of Adverum Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adverum Biotechnologies has recently increased by 35.41%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Adverum Biotechnologies is -0.78. Previous Next 2.5 News and Social Media Coverage News SentimentAdverum Biotechnologies has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Adverum Biotechnologies this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ADVM on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows13 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 86% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $135,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions70.87% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Adverum Biotechnologies are expected to grow in the coming year, from ($1.24) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -1.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Adverum Biotechnologies Stock (NASDAQ:ADVM)Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Read More ADVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADVM Stock News HeadlinesMarch 18, 2024 | globenewswire.comAdverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesMarch 17, 2024 | seekingalpha.comADVM Adverum Biotechnologies, Inc.March 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 14, 2024 | americanbankingnews.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Expands By 35.4%March 14, 2024 | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Raised to "Hold" at StockNews.comMarch 14, 2024 | americanbankingnews.comComparing Adverum Biotechnologies (NASDAQ:ADVM) & BioCryst Pharmaceuticals (NASDAQ:BCRX)March 6, 2024 | finance.yahoo.comADVM Apr 2024 5.000 callMarch 6, 2024 | investorplace.comTurn Pocket Change into Profit: 3 Penny Stocks Ready to PopMarch 18, 2024 | Crypto 101 Media (Ad)Like Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. February 28, 2024 | globenewswire.comAdverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | investorplace.comStocks on the Launchpad: The Next 3 Market SensationsFebruary 25, 2024 | msn.comAdverum Biotechnologies (ADVM) Price Target Increased by 10.53% to 4.28February 22, 2024 | benzinga.comAdverum Biotechnologies Stock (NASDAQ:ADVM), Short Interest ReportFebruary 22, 2024 | investorplace.comUnleash Massive Returns With These 3 Top Penny StocksFebruary 15, 2024 | finance.yahoo.comADVM Feb 2024 4.000 callFebruary 13, 2024 | finance.yahoo.comADVM Sep 2024 2.500 putFebruary 12, 2024 | finance.yahoo.comAdverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 9, 2024 | uk.investing.comAdverum Biotechnologies Inc (ADVM)February 8, 2024 | msn.comWhy Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?February 8, 2024 | finance.yahoo.comAdverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDFebruary 7, 2024 | msn.comAdverum Biotechnologies Awaits Court Decision on SettlementFebruary 6, 2024 | msn.comAdverum Biotechnologies Secures $127.8M in Private PlacementFebruary 6, 2024 | msn.comAdverum Biotechnologies Executes Private Equity PlacementFebruary 5, 2024 | msn.comAdverum Biotechnologies, Cano Health among healthcare moversFebruary 5, 2024 | marketwatch.comAdverum Biotechnologies Shares Soar on Private Placement PricingFebruary 5, 2024 | benzinga.comWhy Adverum Biotechnologies Stock Is Trading HigherFebruary 5, 2024 | finance.yahoo.comAdverum Biotechnologies Announces $127.5 Million Private Placement FinancingSee More Headlines Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADVM CUSIPN/A CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees123Year FoundedN/APrice Target and Rating Average Stock Price Target$4.67 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+166.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-154,540,000.00 Net MarginsN/A Pretax Margin-3,503.14% Return on Equity-88.07% Return on Assets-49.38% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Sales & Book Value Annual Sales$7.50 million Price / Sales48.37 Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book0.96Miscellaneous Outstanding Shares207,160,000Free Float95,673,000Market Cap$362.76 million OptionableOptionable Beta0.88 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Laurent Fischer (Age 60)President, CEO & Director Comp: $977.23kMs. Linda M. Rubinstein M.A. (Age 57)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $111.89kMr. Kishor Peter Soparkar J.D. (Age 53)Chief Operating Officer Comp: $656.96kMr. John W. Rakow J.D. (Age 67)Senior VP & General Counsel Comp: $954.24kDr. Setareh Seyedkazemi Pharm.D. (Age 50)Chief Development Officer Comp: $834.57kDr. R. Andrew Ramelmeier Ph.D. (Age 62)Chief Technology Officer Dr. Romuald Corbau Ph.D. (Age 55)Chief Scientific Officer Ms. Dena HouseChief People OfficerMs. Carla FiankanSenior Vice President of Regulatory AffairsMr. Michael SteelSenior Vice President of QualityMore ExecutivesKey CompetitorsGenfitNASDAQ:GNFTVaxartNASDAQ:VXRTOptheaNASDAQ:OPTBlack Diamond TherapeuticsNASDAQ:BDTXGraphite BioNASDAQ:GRPHView All CompetitorsInsiders & InstitutionsTwin Focus Capital Partners LLCBought 100,000 shares on 3/5/2024Ownership: 0.099%Newtyn Management LLCSold 201,904 shares on 2/15/2024Ownership: 0.815%Citadel Advisors LLCBought 2,500 shares on 2/15/2024Ownership: 0.000%AIGH Capital Management LLCBought 1,848,834 shares on 2/12/2024Ownership: 3.140%Worth Venture Partners LLCBought 452,678 shares on 2/9/2024Ownership: 0.776%View All Insider TransactionsView All Institutional Transactions ADVM Stock Analysis - Frequently Asked Questions Should I buy or sell Adverum Biotechnologies stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADVM shares. View ADVM analyst ratings or view top-rated stocks. What is Adverum Biotechnologies' stock price target for 2024? 3 Wall Street research analysts have issued twelve-month price objectives for Adverum Biotechnologies' stock. Their ADVM share price targets range from $4.00 to $6.00. On average, they anticipate the company's stock price to reach $4.67 in the next year. This suggests a possible upside of 163.7% from the stock's current price. View analysts price targets for ADVM or view top-rated stocks among Wall Street analysts. How have ADVM shares performed in 2024? Adverum Biotechnologies' stock was trading at $0.7528 at the beginning of the year. Since then, ADVM stock has increased by 135.1% and is now trading at $1.77. View the best growth stocks for 2024 here. Are investors shorting Adverum Biotechnologies? Adverum Biotechnologies saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 5,430,000 shares, an increase of 35.4% from the February 14th total of 4,010,000 shares. Based on an average daily volume of 1,810,000 shares, the short-interest ratio is presently 3.0 days. View Adverum Biotechnologies' Short Interest. When is Adverum Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ADVM earnings forecast. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.01. What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO? 3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA). Who are Adverum Biotechnologies' major shareholders? Adverum Biotechnologies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (4.51%), AIGH Capital Management LLC (3.14%), Newtyn Management LLC (0.81%), Worth Venture Partners LLC (0.78%), Dimensional Fund Advisors LP (0.19%) and Twin Focus Capital Partners LLC (0.10%). Insiders that own company stock include Brigit Riley, Dawn Svoronos, James Paul Scopa, Julie Clark, Laurent Fischer, Peter Soparkar, Richard Beckman, Rupert D'souza and Setareh Seyedkazemi. View institutional ownership trends. How do I buy shares of Adverum Biotechnologies? Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADVM) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.